Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients.

Yuti P PatelDonald HusereauNatasha B LeighlBarbara L MeloskyJulian Nam

Published in: Current oncology (Toronto, Ont.) (2021)

Incorporation of TL-LBx-CGP demonstrated an overall impact of $14.7 million with 168 life-years gained to the Canadian publicly funded healthcare system in the 3-year time horizon.

Keyphrases

advanced non small cell lung cancer
newly diagnosed
epidermal growth factor receptor
ejection fraction
healthcare
public health
prognostic factors
ionic liquid
ultrasound guided
health information
risk assessment
dna methylation
health promotion